Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohnʼs disease
- 1 February 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 17 (2), 573-582
- https://doi.org/10.1002/ibd.21345
Abstract
Complementary therapies are frequently used by patients with inflammatory bowel disease (IBD). The aim of this study was to evaluate the efficacy and safety of long-term therapy with a new Boswellia serrata extract (Boswelan, PS0201Bo) in maintaining remission in patients with Crohn's disease (CD). In 22 German centers a double-blind, placebo-controlled, randomized, parallel study was performed. In all, 108 outpatients with CD in clinical remission were included. Patients were randomized to Boswelan (3×2 capsules/day; 400 mg each) or placebo for 52 weeks. The primary endpoint was the proportion of patients in whom remission was maintained throughout the 52 weeks. Secondary endpoints were time to relapse, changes of Crohn's Disease Activity Index (CDAI), and IBD Questionnaire (IBDQ) scores. The trial was prematurely terminated due to insufficient discrimination of drug and placebo with regard to the primary efficacy endpoint. A total of 82 patients were randomized to Boswelan (n = 42) or placebo (n = 40). Sixty-six patients could be analyzed for efficacy. 59.9% of the actively treated patients and 55.3% of the placebo group stayed in remission (P = 0.85). The mean time to diagnosis of relapse was 171 days for the active group and 185 days for the placebo group (P = 0.69). With respect to CDAI, IBDQ, and laboratory measurements of inflammation, no advantages in favor of active treatment were detected. Regarding safety concerns, no disadvantages of taking the drug compared to placebo were observed. The trial confirmed good tolerability of a new Boswellia serrata extract, Boswelan, in long-term treatment of CD. However, superiority versus placebo in maintenance therapy of remission could not be demonstrated. (Inflamm Bowel Dis 2011)Keywords
This publication has 38 references indexed in Scilit:
- Management of Crohn's Disease in AdultsThe American Journal of Gastroenterology, 2009
- S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn”Zeitschrift für Gastroenterologie, 2008
- Boswellic Acids in Chronic Inflammatory DiseasesPlanta Medica, 2006
- Use of complementary and alternative medicine in Germany – a survey of patients with inflammatory bowel diseaseBMC Complementary and Alternative Medicine, 2006
- European evidence based consensus on the diagnosis and management of Crohn's disease: current managementGut, 2006
- Amount of Systemic Steroid Medication Is a Strong Predictor for the Use of Complementary and Alternative Medicine in Patients With Inflammatory Bowel Disease.Inflammatory Bowel Diseases, 2005
- Inhibition of IκB Kinase Activity by Acetyl-boswellic Acids Promotes Apoptosis in Androgen-independent PC-3 Prostate Cancer Cells in Vitro and in VivoPublished by Elsevier BV ,2005
- Complementary and Alternative Medicine Use by Canadian Patients With Inflammatory Bowel Disease: Results From A National SurveyThe American Journal of Gastroenterology, 2003
- Effects of Gum Resin of Boswellia serrata in Patients with Chronic ColitisPlanta Medica, 2001
- Disease Activity Courses in a Regional Cohort of Crohn's Disease PatientsScandinavian Journal of Gastroenterology, 1995